Recruiting

Sleep Gummy

Sponsor:

Olly, PBC

Code:

NCT07932938

Conditions

Sleep Quality

Sleep and Circadian Problems

Eligibility Criteria

Sex: All

Age: 4 - 16

Healthy Volunteers: Accepted

Interventions

Olly melatonin-free supplement

Placebo Supplement

Study Details

Brief summary:

The goal of this clinical trial is to learn if a melatonin-free sleep gummy (a chewable dietary supplement) improves sleep in children aged 4 to 16 whose parents report sleep concerns. It will also learn about the safety and tolerability of the gummy. The main questions it aims to answer are:

1. Does the gummy improve the child's sleep disturbance, compared with a look-alike gummy?
2. Does the gummy change daytime problems linked to poor sleep, sleep habits, and the parent's overall impression of the child's sleep?
3. What medical problems do children have when taking the gummy?

Researchers will compare the sleep gummy to a placebo (a look-alike gummy that contains no active ingredient) to see if the sleep gummy improves sleep.

Participants will:

1. Complete about 1 week of baseline questionnaires and diaries, then take 2 gummies once a day in the evening for 4 weeks, with a parent or guardian supervising
2. Take part from home, with no clinic visits, using the Chloe study app
3. Answer sleep questionnaires every week, a sleep habits questionnaire every 2 weeks, and a safety survey every week
4. Have a parent or guardian keep a daily diary of sleep, naps, mood, activity, and the time the gummies were taken
5. Some participants (an optional group of 60) will also wear a wrist device (a fitness tracker/smartwatch) at night to measure sleep

Conditions

Sleep Quality

Sleep and Circadian Problems

Study ID

NCT07932938

Start date

Nov 13, 2026

Status verified date

Nov, 2026

Completion date

Jul, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 4 - 16

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Child is aged 4 to 16 years, inclusive, at screening.
  • Parent or legal guardian reports current concerns about the child's sleep (for example, difficulty falling asleep, staying asleep, or keeping a consistent sleep routine) and confirms the child has no diagnosed sleep disorder.
  • Parent or legal guardian can read and understand English.
  • Parent or legal guardian can read, understand, and give informed consent on behalf of the child; the child gives age-appropriate assent where applicable.
  • Parent or legal guardian can use a personal smartphone and download Chloe by People Science.
  • Parent or legal guardian can receive shipment of the study product or placebo, and any wearable device, at an address within the United States.
  • Parent or legal guardian can support the child in completing study assessments for up to 11 weeks.
  • Child is willing and able to consume the gummy and can safely chew and swallow gummy products.
  • Parent or legal guardian agrees to keep the child's current lifestyle, diet, bedtime routine, and physical activity for the whole study.
  • Child has a regular sleep-wake cycle with a consistent bedtime and wake time (within about 1 hour on weekdays and weekends) for at least 3 weeks before baseline, and agrees to keep this schedule during the study.

Exclusion Criteria:

  • No personal smartphone, no internet access, or unwilling to download Chloe.
  • Child has a diagnosed sleep disorder needing medical management (for example, obstructive sleep apnea, narcolepsy, or restless leg syndrome).
  • Child snores loudly on most nights, has been seen to stop breathing, gasp, or choke during sleep, or has been referred for a sleep evaluation that is not yet complete.
  • Use of melatonin, prescription sleep medication, or other sleep aids (including over-the-counter antihistamines used for sleep and CBD or hemp products) within 28 days before screening, or expected use during the study.
  • Regular caffeine intake of more than 1 caffeinated beverage (over 110 mg) per day, or unwillingness to keep caffeine intake stable and avoid caffeine after mid-afternoon.
  • Use of a standalone magnesium supplement, or any dietary supplement marketed for sleep, stress, relaxation, mood, or focus, within 30 days before randomization or during the study. A stable-dose standard children's multivitamin is allowed.
  • Any investigational therapy within 30 days before randomization.
  • Known allergy or hypersensitivity to any study product or placebo ingredient, to Asteraceae (daisy family) plants, or to soy, egg, peanut, tree nuts, shellfish, milk, wheat, or sesame.
  • Any medical, neurodevelopmental, or psychiatric condition that, in the Principal Investigator's opinion, may confound sleep outcomes or affect participation.
  • Significant illness, disease, or condition that, in the Principal Investigator's opinion, may affect participation or outcomes.
  • Unlikely to be able to comply with the study, or considered unsuited by the Principal Investigator.
  • History or presence of a clinically diagnosed neurologic, cardiac, renal, hepatic, endocrine (including diabetes), pulmonary, biliary, or gastrointestinal condition. Well-controlled asthma managed with as-needed medication, seasonal allergies, and mild eczema are not exclusions.
  • Body mass index at or above the 95th percentile for age and sex.
  • Use of angiotensin-converting enzyme inhibitors, other magnesium-retaining drugs, or potassium-sparing diuretics.
  • Other diseases or medications that might interfere with the study or put the participant's health at risk.
  • Immune insufficiency (such as selective IgA deficiency, common variable immunodeficiency, or X-linked agammaglobulinemia).
  • Taking any prescription medication or dietary supplement for anxiety, depression, mood, stress, focus, or attention-deficit/hyperactivity disorder.
  • Known liver dysfunction.
  • Use of systemic corticosteroids or immunosuppressant drugs.
  • History of cancer within the past 5 years.
  • Planned surgery or invasive medical procedures during the study.
  • Planned travel during baseline or the use period that involves a time zone change or 2 or more consecutive nights away from the usual sleep environment.
  • Parent or legal guardian cannot communicate with the study team or complete study procedures, or child has a condition that would prevent completing assent or assessments.
  • Child or household member of an employee of People Science or the Sponsor (Unilever/Olly).
  • Pregnant or breastfeeding (self-reported).
  • Another child in the same household is already enrolled.

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

active comparator: Active Product

Under parent/guardian supervision, participant takes 2 gummies once per evening for 4 weeks.

placebo comparator: Placebo

Under parent/guardian supervision, participants 2 gummies oncer per evening for 4 weeks

Interventions

Olly melatonin-free supplement

Melatonin-free supplement intended for children who experience mild-to-moderate sleep concerns. Contains magnesium, l-theanine, lemon balm extract, and chamomile.

Placebo Supplement

The placebo gummy matches the study product in appearance, flavor, texture, and packaging and contains no active ingredients.

Primary outcome measure

  • Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Sleep Disturbance T-Score [ Time Frame: Baseline and weekly through Week 4 of the product or placebo use period ]

Central Contacts and Locations

Central contacts

Locations

People Science, Inc.

Recruiting

Los Angeles, California, United States, 90045

Contacts

Principal Investigator:

Noah Craft, MD, PhD

More Information

Sponsor

Olly, PBC

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • pediatric
  • sleep disturbance
  • sleep impairment
  • sleep habits
  • adolescents
  • dietary supplement
  • magnesium
  • theanine
  • lemon balm
  • chamomile
  • melatonin-free
  • decentralized clinical trial
  • children
  • supplement

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Olly, PBC on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.